Multimeric il-15 soluble fusion molecules and methods of making and using same

Patent metadata

Field	Value
Publication number	US-2020181237-A1
Application number	US-202016749967-A
Country	US
Kind code	A1
Filing date	Jan 22, 2020
Priority date	Sep 21, 2010
Publication date	Jun 11, 2020
Grant date	—

Abstract

The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).

First claim

1 - 20 . (canceled)

21 . A method for treating human immunodeficiency virus (HIV) infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an interleukin-15N72D:IL-15 receptor alpha Sushi/Fc (IL-15N72D:IL-15RαSu/Fc) complex, wherein the complex comprises a dimeric IL-15RαSu/Fc and two IL-15N72D molecules (ALT-803).

22 . The method of claim 21 , wherein the IL-15RαSu/Fc comprises SEQ ID NO: 1.

23 . The method of claim 21 , wherein a IL-15N72D molecule comprises SEQ ID NO: 2.

24 . The method of claim 21 , wherein the effective amount is between about 1 and 20 μg/kg.

25 . The method of claim 24 , wherein the effective amount is about 1 μg/kg.

26 . The method of claim 24 , wherein the effective amount is 10 μg/week.

27 . The method of claim 21 , wherein the effective amount is between about 20 μg and 100 μg/kg.

28 . The method of claim 24 , wherein the effective amount is about 5 μg/kg.

29 . The method of claim 24 , wherein the effective amount is about 10 μg/kg.

30 . The method of claim 24 , wherein the effective amount is about 15 μg/kg.

31 . The method of claim 24 , wherein the effective amount is about 20 μg/kg.

32 . The method of claim 27 , wherein the effective amount is about 30 μg/kg.

33 . The method of claim 27 , wherein the effective amount is about 50 μg/kg.

34 . The method of claim 27 , wherein the effective amount is about 75 μg/kg.

35 . The method of claim 27 , wherein the effective amount is about 100 μg/kg.

36 . The method of claim 21 , wherein ALT-803 is administered once, twice, or three times per week.

37 . The method of claim 21 , wherein the pharmaceutical composition is administered systemically, intravenously, or by instillation.

Assignees

• Altor Bioscience Llc

Inventors

• Wong Hing C
• Rhode Peter
• Liu Bai
• Zhu Xiaoyun
• Han Kai-Ping

Classifications

• A61K38/2086

  IL-13 to IL-16 · CPC title

• C12P21/00

  Preparation of peptides or proteins (single cell protein C12N1/00) · CPC title

• A61P37/02

  Immunomodulators · CPC title

• C07K14/001

  by chemical synthesis · CPC title

• A61K38/17

  from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title